Status:
COMPLETED
Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels
Lead Sponsor:
Central Park Medical College
Conditions:
LDL - Low Density Lipoprotein Receptor Disorder
Rosuvastatin
Eligibility:
All Genders
30+ years
Phase:
NA
Brief Summary
Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels
Eligibility Criteria
Inclusion
- patients who were already on statins
Exclusion
- hereditary diseases including familial hypercholesterolemia and kidney diseases
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT06910098
Start Date
December 1 2023
End Date
August 31 2024
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Park Teaching Hospital
Lahore, Pakistan, 54600